APPEALS CONFERENCE DOCUMENT BINDER

APPEALS CONFERENCE DOCUMENT BINDER
ATTENDEE LIST
(Inside Front Cover)
The following individuals are expected to attend the Appeals Conference scheduled for February 28, 2024, at the IRS Appeals Office, Manhattan, New York:
Calderwood & Harkness LLP (Counsel for Penterra Pharmaceuticals Corp.)
Penterra Pharmaceuticals Corp. (Taxpayer)
Whitmore Valuation Group LLC (Economic Expert)
Internal Revenue Service — Appeals
Note: Additional IRS personnel may attend at the discretion of Appeals Officer Castañeda. Taxpayer reserves the right to bring additional representatives upon reasonable notice to Appeals. IRS Form 2848 (Power of Attorney) authorizing Calderwood & Harkness LLP representatives is included at Tab 4.5 of this binder.
MASTER TABLE OF CONTENTS
Right-click to update Table of Contents
VOLUME I — PROTEST AND PROCEDURAL DOCUMENTS
Volume I contains the Formal Protest filed on behalf of Penterra Pharmaceuticals Corp. on December 22, 2023, together with supporting exhibits, the IRS Notice of Proposed Adjustment, the 30-Day Letter and related procedural correspondence, and Consents to Extend the Statute of Limitations. These documents establish the procedural posture of the case before the Appeals Officer and provide the foundational factual and legal framework for the taxpayer's defense of its transfer pricing positions for Tax Years 2017 through 2020.
Tab 1 — Formal Protest (Filed December 22, 2023)
The Formal Protest constitutes Penterra Pharmaceuticals Corp.'s comprehensive response to the IRS's proposed adjustments totaling $380,400,000 across all four examination years. The Protest sets forth the taxpayer's statement of facts, legal arguments, and defenses under IRC § 482 and the applicable Treasury Regulations, including defenses of the cost-sharing arrangement ratios, the arm's-length royalty rate on legacy intangible property, the platform contribution transaction valuation, the economic substance and DEMPE functions of Penterra Biosciences Ireland DAC, and the taxpayer's penalty protection position.
Tab 2 — Protest Exhibits
The Protest Exhibits provide the supporting documentary evidence referenced in the Formal Protest. These exhibits include the corporate structure chart, a summary of the cost-sharing arrangement, summaries of the economic analyses, evidence of PBI's economic substance, and penalty protection documentation.
Tab 3 — IRS Notice of Proposed Adjustment (NOPA)
Tab 3 contains the IRS Notice of Proposed Adjustment issued on October 12, 2023, by the LB&I Northeast Transfer Pricing Practice examination team, covering all four tax years at issue. The NOPA sets forth the IRS's proposed adjustments to PPC's taxable income under IRC § 482, the schedule of proposed adjustments, the IRS's proposed CSA cost-sharing percentages, the IRS's proposed royalty rate, and the IRS's proposed penalty.
Tab 4 — 30-Day Letter and Procedural Correspondence
Tab 4 contains the 30-Day Letter issued by the IRS examination team, together with procedural correspondence relating to the filing of the Protest, the request for an Appeals conference, and the Power of Attorney authorizing Calderwood & Harkness LLP to represent Penterra Pharmaceuticals Corp. before the IRS.
Tab 5 — Consent to Extend Statute of Limitations
Tab 5 contains the executed Consents to Extend the Time to Assess Tax (IRS Form 872) for Tax Years 2017 and 2018, together with a tracking summary of the statute of limitations for all four examination years. Extensions were required for Tax Years 2017 and 2018, whose original three-year assessment periods would otherwise have expired prior to the resolution of the Appeals process. Tax Years 2019 and 2020 remain within the original three-year assessment period.
Note: For Tax Years 2019 and 2020, the original three-year assessment periods have not yet expired and no extensions have been executed. Calderwood & Harkness LLP is monitoring the statute of limitations for all four years and will advise PPC if additional extensions become necessary.
VOLUME II — ECONOMIC ANALYSES AND EXPERT REPORTS
Volume II contains the economic analyses and expert reports prepared by Whitmore Valuation Group LLC in support of Penterra Pharmaceuticals Corp.'s transfer pricing positions. These reports address the arm's-length royalty rate for the Legacy IP License Agreement (CUT analysis), PBI's operating margins (CPM/TNMM analysis), the PCT valuation (income method / DCF approach), the WACC determination, benchmarking data, cost-sharing ratio calculations, revenue projection analyses, the legacy IP royalty financial model, the rebuttal of the IRS economist's analysis, and a summary of the IRS's proposed adjustments. The economic analyses were prepared by Dr. Helena Vasquez, Managing Director of Whitmore Valuation Group LLC, and her team, in coordination with Calderwood & Harkness LLP.
Tab 6 — CUT Analysis — Legacy IP Royalty Rate
The comparable uncontrolled transaction analysis supports the taxpayer's 4.5% royalty rate on the Legacy IP License Agreement and demonstrates that this rate falls within the arm's-length range established by comparable pharmaceutical license agreements.
Tab 7 — CPM / TNMM Analysis — PBI Operating Margins
The CPM/TNMM analysis provides an independent verification of PBI's profitability levels against comparable uncontrolled companies, confirming that PBI's operating margins are consistent with arm's-length results.
Tab 8 — PCT Valuation Analysis — Income Method / DCF
The PCT valuation analysis supports the $312,000,000 platform contribution transaction payment made by PBI upon entry into the cost-sharing arrangement, applying the income method (Discounted cash flow approach) as required by Treas. Reg. § 1.482-7(g)(4).
Tab 9 — Discount Rate / WACC Technical Analysis
Tab 9 contains a standalone technical memorandum on the WACC determination, addressing the central dispute between the taxpayer and the IRS on the appropriate discount rate for valuing pharmaceutical intangible property.
Tab 10 — Benchmarking Data
Tab 10 contains the underlying benchmarking data supporting the CUT analysis and the CPM/TNMM analysis, including the search criteria, screening methodology, financial data, and comparable profiles.
Tab 11 — Cost-Sharing Ratio Analysis
Tab 11 presents the detailed analysis supporting PBI's cost-sharing percentages under the CSA, based on reasonably anticipated benefit projections.
The workbook includes the underlying revenue projections by product and territory that support these percentages, including the methodology for projecting non-Americas revenues as a share of total global revenues.
Tab 12 — Revenue Projection Analysis
Tab 12 contains the revenue projection analyses that underlie the cost-sharing ratio calculations and the PCT valuation, including product-level data for each of PPC's three principal products.
Note: The declining trend in legacy compound net sales reflects the maturation of the legacy product portfolio, patent expiries on certain legacy compounds, and increasing generic competition in non-Americas markets.
Tab 13 — Legacy IP Royalty Financial Model
Tab 13 presents a financial model comparing the royalty payments under PPC's 4.5% rate with those that would result from the IRS's proposed 11.0% rate, quantifying the royalty adjustment at issue.
Tab 14 — Rebuttal of IRS Economist's Analysis (Dr. Alan Washburne)
Tab 14 contains the taxpayer's rebuttal of the economic analysis prepared by IRS Economist Dr. Alan Washburne in support of the IRS's proposed adjustments.
Tab 15 — Summary of IRS Proposed Adjustments
Tab 15 presents a comprehensive summary workbook of the IRS's proposed adjustments, broken down by issue and year, together with tax and penalty impact calculations.
Note: Interest on the underpayment will accrue at the applicable federal underpayment rate from the original due date of each return through the date of payment. Interest calculations are not included in this summary but are addressed in the settlement analysis at Tab 28.
VOLUME III — PBI ECONOMIC SUBSTANCE AND FUNCTIONAL ANALYSIS
Volume III presents comprehensive evidence demonstrating that Penterra Biosciences Ireland DAC is a substantial operating entity with genuine economic substance, meaningful decision-making authority, and significant DEMPE (Development, Enhancement, Maintenance, Protection, and Exploitation) functions with respect to the cost-shared intangible property in non-Americas territories. This evidence is critical to the taxpayer's defense against the IRS's implicit challenge to the allocation of profits to PBI and supports the taxpayer's position that PBI's functions, assets, and risks justify the income attributed to it under the intercompany arrangements.
Tab 16 — Functional Analysis — PBI (2017–2020)
Tab 17 — DEMPE Functions Matrix
Tab 18 — PBI Personnel and Headcount Evidence
Tab 19 — PBI Board Governance Evidence
Tab 20 — PBI Physical Presence and Operational Evidence
Tab 21 — PMI Contract Manufacturing Arrangement
VOLUME IV — LEGAL AUTHORITIES
Volume IV compiles the legal authorities upon which Penterra Pharmaceuticals Corp. relies in support of its transfer pricing positions, including the relevant provisions of the Internal Revenue Code, Treasury Regulations, case law, revenue procedures and administrative guidance, and the OECD Transfer Pricing Guidelines. These authorities are organized by category and are cross-referenced to the specific arguments presented in the Formal Protest at Tab 1.
Tab 22 — Statutes
Tab 23 — Treasury Regulations
Tab 24 — Case Law
Tab 25 — Revenue Procedures and Administrative Guidance
Tab 26 — OECD Transfer Pricing Guidelines
VOLUME V — SETTLEMENT AND FINANCIAL ANALYSIS
Volume V contains settlement and financial analyses prepared by Calderwood & Harkness LLP for use by the taxpayer's representatives at the Appeals conference. Tabs 27 and 28 contain materials protected by the attorney-client privilege and attorney work product doctrine and are not for production to the IRS.
NOTICE: Tabs 27 and 28 are marked ATTORNEY-CLIENT PRIVILEGED / ATTORNEY WORK PRODUCT — NOT FOR PRODUCTION. These materials are included in the taxpayer's counsel binder only and are not to be provided, disclosed, or made available to IRS Appeals or any other government representative under any circumstances.
Tab 27 — Hazards of Litigation Analysis
ATTORNEY-CLIENT PRIVILEGED / ATTORNEY WORK PRODUCT — NOT FOR PRODUCTION
Tab 28 — Settlement Analysis and Financial Impact
ATTORNEY-CLIENT PRIVILEGED / ATTORNEY WORK PRODUCT — NOT FOR PRODUCTION
Note: Interest and penalty calculations for each scenario are included in the full workbook but are redacted from this table of contents for brevity. Interest is calculated at the applicable federal underpayment rate from the original due date of each return through an assumed settlement date.
Tab 29 — Correlative Adjustment Analysis
Tab 30 — TCJA and Cross-Border Tax Considerations
VOLUME VI — BACKGROUND DOCUMENTS
Volume VI contains background documents providing the factual context for the transfer pricing examination, including corporate and entity information, intercompany agreements, key product information, the IRS examination procedural history, contemporaneous transfer pricing documentation, and reserved space for supplemental evidence.
Tab 31 — Corporate and Entity Information
Tab 32 — Intercompany Agreements
Tab 33 — Key Product Information
Tab 34 — IRS Examination Procedural History
•  Opening Conference (June 28, 2022): Attended by Cross, Simmons, Whitfield, Staines, Meskill, and Dunleavy. Topics discussed included the scope of the examination, the anticipated timeline, the IDR process, and the identification of the principal transfer pricing issues.
•  Mid-Examination Conference (May 25, 2023): Attended by Cross, Simmons, Whitfield, Meskill, Dunleavy, and Washburne. Topics discussed included the status of the examination, preliminary positions of the IRS examination team, and areas of potential agreement and disagreement.
•  IRS Economist Meeting (August 15, 2023): Attended by Cross, Simmons, Dr. Vasquez (Whitmore Valuation Group), Washburne, and Dunleavy. Topics discussed included the economic analyses of both parties, the CUT selection criteria, the WACC determination, and the revenue projection methodology.
•  Chief Counsel Call (September 20, 2023): Attended by Cross, Hartwell, Simmons, Rosario, Hirabayashi, and Meskill. Topics discussed included the legal framework for the proposed adjustments, the penalty position, and the procedural path to the NOPA.
Tab 35 — Contemporaneous Transfer Pricing Documentation
Tab 36 — Supplemental Evidence — Additional CUT Comparables
INDEX OF EXHIBITS — CROSS-REFERENCE TABLE
The following master cross-reference table maps each binder tab to the corresponding section of the Formal Protest, the relevant IDR response(s), and the supporting economic report(s), facilitating efficient navigation of the binder during the Appeals conference.
Note on Privileged Materials: Tabs 27 and 28 are marked ATTORNEY-CLIENT PRIVILEGED / ATTORNEY WORK PRODUCT — NOT FOR PRODUCTION. These tabs contain privileged analyses prepared by Calderwood & Harkness LLP for the purpose of advising Penterra Pharmaceuticals Corp. in connection with the IRS Appeals process. These materials have not been Bates-stamped and are not included in the production set. These tabs are maintained in the counsel's copy of the binder only and must not be disclosed, produced, or made available to IRS Appeals or any other government representative under any circumstances. Inadvertent disclosure of these materials does not constitute a waiver of the attorney-client privilege or attorney work product protection.
BACK COVER — CONTACT INFORMATION
Calderwood & Harkness LLP
Leonard Cross, Esq. Responsible Partner 1735 Market Street, Suite 3100 Philadelphia, PA 19103 Tel: (215) 864-7200
Fax: (215) 864-7201
Email: lcross@calderwoodharkness.com
Sylvia Hartwell, Esq. Billing Partner 600 Lexington Avenue New York, NY 10022 Tel: (212) 546-3800
Fax: (212) 546-3801
Email: shartwell@calderwoodharkness.com
Garrett Simmons, Esq. Lead Associate 1735 Market Street, Suite 3100 Philadelphia, PA 19103 Tel: (215) 864-7245
Fax: (215) 864-7201
Email: gsimmons@calderwoodharkness.com
Whitmore Valuation Group LLC
Dr. Helena Vasquez Managing Director 200 Ashbury Asset Advisors, Suite 700 Boston, MA 02109 Tel: (617) 338-4500
Fax: (617) 338-4501
Email: hvasquez@whitmorevaluation.com
Penterra Pharmaceuticals Corp.
Marcus Whitfield Vice President, Global Tax 2200 Independence Boulevard Princeton Junction, NJ 08550 Tel: (609) 452-6100
Fax: (609) 452-6101
Email: mwhitfield@penterra.com
This Appeals Conference Document Binder was prepared by Calderwood & Harkness LLP on behalf of Penterra Pharmaceuticals Corp. for the sole purpose of the IRS Appeals Conference scheduled for February 28, 2024. All materials contained in this binder are confidential and are subject to the attorney-client privilege and/or attorney work product doctrine except as otherwise indicated. Any unauthorized use, disclosure, or distribution of the contents of this binder is strictly prohibited.
© 2024 Calderwood & Harkness LLP. All rights reserved.
Name | Role
Leonard Cross, Esq. | Responsible Partner
Sylvia Hartwell, Esq. | Billing Partner
Garrett Simmons, Esq. | Lead Associate
Name | Role
Marcus Whitfield | Vice President, Global Tax
Deborah Staines, Esq. | General Counsel
Name | Role
Dr. Helena Vasquez | Managing Director / Lead Economist
Name | Role
Noreen Castañeda | Appeals Officer
Sub-Tab | Document Description
1.1 | Formal Protest — Penterra Pharmaceuticals Corp., filed December 22, 2023, contesting proposed adjustments totaling $380,400,000 for Tax Years 2017, 2018, 2019, and 2020 under IRC § 482. The Protest was filed with the Office of Appeals pursuant to the 30-Day Letter dated November 8, 2023, as extended by agreement of the IRS to December 22, 2023. The Protest identifies the taxpayer, states the relevant tax years and proposed adjustments, and requests a conference with the Office of Appeals.
1.2 | Statement of Facts. Comprehensive factual narrative setting forth the corporate structure of Penterra Pharmaceuticals Corp. and its relevant affiliates, including Penterra Holdings Luxembourg S.à r.l. ("PHL"), Penterra Biosciences Ireland DAC ("PBI"), and Penterra Manufacturing Ireland Ltd. ("PMI"). The Statement of Facts describes the formation and operation of the qualified cost-sharing arrangement entered into effective July 1, 2012, the platform contribution transaction payment of $312,000,000, the legacy IP license agreement and associated royalty rate of 4.5% of net sales, and the operational activities of PBI in Dublin, Ireland, including the growth of PBI's workforce, regulatory capabilities, and commercial activities across 68 non-Americas country markets during the examination period.
1.3 | Law and Argument — Transfer Pricing Defense under IRC § 482, Treas. Reg. §§ 1.482-4, 1.482-7, and 1.482-1(d). This section presents the taxpayer's comprehensive legal arguments in support of its transfer pricing positions, including the application of the arm's-length standard, the best method rule, the selection and application of the comparable uncontrolled transaction method for the legacy IP royalty rate, the comparable profits method / transactional net margin method for testing PBI's operating margins, and the income method (Discounted cash flow approach) for the platform contribution transaction valuation. The section addresses the regulatory framework governing qualified cost-sharing arrangements under Treas. Reg. § 1.482-7 and demonstrates that the taxpayer's intercompany pricing is consistent with arm's-length results under each applicable method.
1.4 | Defense of CSA Cost-Sharing Ratios (PBI's Share: 38.2%–42.7%). The Protest defends PBI's cost-sharing percentages for each of the four examination years (2017: 38.2%; 2018: 39.6%; 2019: 41.1%; 2020: 42.7%), which are based on reasonably anticipated benefit projections reflecting PBI's share of non-Americas revenue relative to global revenue from cost-shared intangibles. The defense demonstrates that the taxpayer's cost-sharing ratios are calculated in accordance with Treas. Reg. § 1.482-7(e) and that the IRS's proposed ratios (48.2%, 50.6%, 52.3%, and 53.7%, respectively) are based on unsupported upward adjustments to PBI's reasonably anticipated benefits and a flawed revenue attribution methodology.
1.5 | Defense of Arm's-Length Royalty Rate (4.5% of Net Sales on Legacy IP). The Protest defends the 4.5% royalty rate charged to PBI under the Legacy IP License Agreement for the exploitation of pre-CSA intangible property in non-Americas territories. The defense relies on a comparable uncontrolled transaction analysis identifying 14 comparable pharmaceutical license agreements, the interquartile range of which (3.1%–6.8%, median 4.4%) encompasses the taxpayer's 4.5% rate. The Protest rebuts the IRS's proposed increase of the royalty rate to 11.0%, which the taxpayer contends is based on non-comparable license agreements involving intangible property of materially different value, risk profiles, and stages of commercial exploitation.
1.6 | Defense of PCT Valuation ($312,000,000). The Protest defends the $312,000,000 platform contribution transaction ("PCT") payment made by PBI upon entry into the cost-sharing arrangement effective July 1, 2012. The taxpayer's valuation, prepared using the income method / Discounted cash flow approach with a weighted-average cost of capital of 9.8%, produces an arm's-length range of $278,000,000 to $361,000,000, within which the $312,000,000 actual payment falls. The defense identifies and critiques the IRS's income-method valuation of $852,000,000, which the taxpayer contends is based on an inappropriately low discount rate of 7.2%, overstated non-Americas revenue growth projections, and other methodological errors.
1.7 | Defense of PBI Economic Substance and DEMPE Functions. The Protest presents evidence that PBI possesses genuine economic substance and performs meaningful development, enhancement, maintenance, protection, and exploitation ("DEMPE") functions with respect to the cost-shared intangible property, supporting the allocation of profits to PBI consistent with the arm's-length standard. The defense describes PBI's growth from 52 employees at inception in 2012 to 185 employees by 2020; the conduct of 42 board meetings in Dublin during the examination period; cumulative regulatory expenditures of €47,200,000; PBI's approximately 18,000 square foot office at Sandyford Business Park, Dublin; PBI's independent pricing authority across 68 non-Americas country markets; the role and authority of Managing Director Aidan Naughton; and PBI's independent banking operations with Glenmore Bank Ireland plc.
1.8 | Contemporaneous Documentation and Penalty Protection under IRC § 6662(e)(3)(B). The Protest establishes that Penterra Pharmaceuticals Corp. maintained contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP for all four examination years (2017, 2018, 2019, and 2020), satisfying the requirements for penalty protection under IRC § 6662(e)(3)(B). The documentation was prepared on a timely basis and supports the taxpayer's transfer pricing positions with appropriate economic analyses and application of recognized transfer pricing methods.
1.9 | Penalties Appendix — Reasonable Cause Defense. The Penalties Appendix presents the taxpayer's reasonable cause defense under IRC § 6664(c) in the event the IRS's proposed penalty under IRC § 6662(e) is sustained in whole or in part. The defense demonstrates that the taxpayer acted in good faith and with reasonable cause in determining its transfer pricing positions, having relied on the advice of qualified professionals (Crestfield & Associates LLP for contemporaneous documentation and Whitmore Valuation Group LLC for economic analyses) and having maintained detailed contemporaneous records.
Sub-Tab | Document Description
2.A | Exhibit A — PPC Corporate Structure Chart. Diagram depicting the ownership structure of Penterra Pharmaceuticals Corp. ("PPC"), a Delaware corporation publicly traded on Nasdaq (ticker: PPCA), and its relevant foreign affiliates. PPC is the 100% owner of Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under Luxembourg law (RCS No. B 168452), which is treated as a disregarded entity for U.S. federal income tax purposes. PHL is the 100% owner of Penterra Biosciences Ireland DAC ("PBI"), a designated activity company organized under Irish law. PBI, in turn, is the 100% owner of Penterra Manufacturing Ireland Ltd. ("PMI"), an Irish private limited company. The structure chart identifies the jurisdiction of organization, the entity type, and the intercompany relationship (including disregarded entity status) for each entity in the chain.
2.B | Exhibit B — Summary of Cost-Sharing Arrangement. Summary of the qualified cost-sharing arrangement ("CSA") entered into between PPC and PBI, effective July 1, 2012, under which PBI acquired the right to exploit cost-shared intangible property in non-Americas territories. The CSA provides for a platform contribution transaction ("PCT") payment of $312,000,000 from PBI to PPC. PBI's cost-sharing percentages for the examination years, based on reasonably anticipated benefits, are as follows: 2017: 38.2% of $487,300,000 total qualified R&D costs = $186,150,000; 2018: 39.6% of $523,800,000 = $207,420,000; 2019: 41.1% of $561,200,000 = $230,650,000; 2020: 42.7% of $598,400,000 = $255,520,000. The scope of the CSA covers the development and exploitation of intangible property relating to PPC's oncology, immunology, and rare disease product portfolio in non-Americas territories.
2.C | Exhibit C — Summary of Economic Analyses. Summary of the economic analyses prepared by Whitmore Valuation Group LLC in support of PPC's transfer pricing positions, including: (i) CUT analysis of the Legacy IP royalty rate, identifying 14 comparable pharmaceutical license agreements, with an interquartile range of 3.1%–6.8% and median of 4.4%, supporting the taxpayer's 4.5% royalty rate; (ii) CPM/TNMM analysis of PBI's operating margins, using 22 comparable companies, demonstrating that PBI's margins fall within the interquartile range in all four examination years; and (iii) DCF analysis of the PCT valuation, using a WACC of 9.8%, producing an arm's-length range of $278,000,000–$361,000,000 and supporting the $312,000,000 actual payment.
2.D | Exhibit D — Evidence of PBI Economic Substance. Compilation of evidence demonstrating that PBI is a substantial operating entity with genuine economic substance. Key evidence includes: (i) headcount growth from 52 employees at inception in 2012 to 185 employees by year-end 2020; (ii) 42 board meetings held in Dublin during the 2017–2020 examination period; (iii) cumulative regulatory expenditures of €47,200,000 across 68 non-Americas country markets during 2017–2020; (iv) PBI's physical office of approximately 18,000 square feet at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4; (v) PBI's independent pricing decisions across 68 country markets; (vi) PBI Managing Director Aidan Naughton's role, authority, and tenure; and (vii) PBI's independent banking relationship with Glenmore Bank Ireland plc.
2.E | Exhibit E — Penalty Protection Documentation. Summary of the contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP for Tax Years 2017, 2018, 2019, and 2020. The documentation was prepared in accordance with the requirements of IRC § 6662(e)(3)(B) and Treas. Reg. § 1.6662-6(d), providing a reasonable cause defense against the imposition of penalties under IRC § 6662(e). The documentation was prepared under the direction of Engagement Partner Martin Ogilvy, CPA, and Transfer Pricing Partner Susan Lam, CPA, of Crestfield & Associates LLP, and was completed on a timely basis for each examination year.
Sub-Tab | Document Description
3.1 | IRS Notice of Proposed Adjustment ("NOPA"), dated October 12, 2023, covering Tax Years 2017, 2018, 2019, and 2020. The NOPA proposes adjustments to Penterra Pharmaceuticals Corp.'s taxable income under IRC § 482 in connection with intercompany transactions between PPC and its Irish subsidiary, Penterra Biosciences Ireland DAC. The NOPA was prepared by the LB&I Northeast Transfer Pricing Practice examination team (Team ID: LB&I-NE-TP-2022-00641), under the supervision of Supervisory Revenue Agent Gerald Meskill, and was reviewed by IRS Chief Counsel Attorney-Advisor Franklin Rosario.
3.2 | Schedule of Proposed Adjustments. The NOPA proposes the following adjustments to PPC's taxable income:
Adjustment Category | Amount
CSA Cost-Sharing Adjustments (PBI share increase) | $235,010,000
Royalty Rate Adjustments (4.5% → 11.0%) | $188,040,000
Correlative Offset (avoiding double-counting) | ($42,650,000)
Net Proposed Adjustment | $380,400,000
Sub-Tab | Document Description
3.3 | IRS Proposed CSA Cost-Sharing Percentages by Year. The IRS proposes to increase PBI's cost-sharing percentages from the taxpayer-reported percentages as follows:
Tax Year | PPC Position | IRS Position | Difference
2017 | 38.2% | 48.2% | +10.0%
2018 | 39.6% | 50.6% | +11.0%
2019 | 41.1% | 52.3% | +11.2%
2020 | 42.7% | 53.7% | +11.0%
Sub-Tab | Document Description
3.4 | IRS Proposed Royalty Rate Increase. The IRS proposes to increase the arm's-length royalty rate on the Legacy IP License Agreement from PPC's reported rate of 4.5% of net sales to 11.0% of net sales, an increase of 6.5 percentage points. The IRS's proposed rate is based on an alternative comparable uncontrolled transaction analysis conducted by IRS Economist Dr. Alan Washburne, which the taxpayer contends relies on non-comparable license agreements and fails to make appropriate comparability adjustments.
3.5 | IRS Proposed Penalty — IRC § 6662(e) Substantial Valuation Misstatement. The IRS proposes a 20% penalty under IRC § 6662(e) for substantial valuation misstatement attributable to transfer pricing. The penalty is calculated on the underpayment of tax attributable to the proposed adjustment: $380,400,000 × 21% statutory corporate tax rate = $79,884,000 underpayment; 20% penalty = $15,977,000 (rounded). The IRS has not asserted the 40% gross valuation misstatement penalty under IRC § 6662(h).
Sub-Tab | Document Description
4.1 | 30-Day Letter, dated November 8, 2023, issued by Supervisory Revenue Agent Gerald Meskill on behalf of the LB&I Northeast Transfer Pricing Practice examination team. The 30-Day Letter transmits the NOPA and informs PPC of its right to file a written protest and request a conference with the IRS Office of Appeals within 30 days.
4.2 | Letter from Leonard Cross, Esq. (Calderwood & Harkness LLP) to Supervisory Revenue Agent Gerald Meskill, dated November 15, 2023, requesting a 30-day extension to file PPC's Formal Protest. The letter requests an extension from December 8, 2023, to January 8, 2024, citing the complexity of the proposed adjustments, the volume of supporting documentation, and the need to coordinate with the taxpayer's economic expert.
4.3 | IRS grant of extension to file Formal Protest, dated November 22, 2023. The IRS granted PPC an extension to December 22, 2023 (rather than the requested January 8, 2024), to file its Formal Protest. The letter was issued by Supervisory Revenue Agent Gerald Meskill.
4.4 | Letter from Leonard Cross, Esq. (Calderwood & Harkness LLP) to Appeals Officer Noreen Castañeda, dated January 10, 2024, requesting a conference with the IRS Office of Appeals. The letter identifies the issues to be addressed at the conference, the expected attendees, and the taxpayer's preference for an in-person conference in Manhattan, New York.
4.5 | IRS Form 2848 — Power of Attorney and Declaration of Representative, filed June 8, 2022. The Form 2848 authorizes the following representatives to act on behalf of Penterra Pharmaceuticals Corp. (EIN: 22-3741856) for Tax Years 2017, 2018, 2019, and 2020: Leonard Cross, Esq.; Sylvia Hartwell, Esq.; Garrett Simmons, Esq.; and Fatima Nazari, Esq. (all of Calderwood & Harkness LLP).
Sub-Tab | Document Description
5.1 | IRS Form 872 — Consent to Extend the Time to Assess Tax for Tax Year 2017. Executed by Marcus Whitfield, VP Global Tax, on behalf of Penterra Pharmaceuticals Corp., and by Supervisory Revenue Agent Gerald Meskill on behalf of the IRS. The statute of limitations for Tax Year 2017 is extended through December 31, 2024.
5.2 | IRS Form 872 — Consent to Extend the Time to Assess Tax for Tax Year 2018. Executed by Marcus Whitfield, VP Global Tax, on behalf of Penterra Pharmaceuticals Corp., and by Supervisory Revenue Agent Gerald Meskill on behalf of the IRS. The statute of limitations for Tax Year 2018 is extended through December 31, 2024.
5.3 | Statute of Limitations Tracking Summary for Tax Years 2017–2020. The tracking summary identifies the original return filing date, the original three-year statute expiration date, and any extensions for each examination year, as follows:
Tax Year | Return Filed | Original Expiration | Extended Expiration
2017 | October 15, 2018 | October 15, 2021 | December 31, 2024
2018 | October 15, 2019 | October 15, 2022 | December 31, 2024
2019 | October 15, 2020 | October 15, 2023 | N/A (within period)
2020 | October 15, 2021 | October 15, 2024 | N/A (within period)
Sub-Tab | Document Description
6.1 | Whitmore Valuation Group LLC — Comparable Uncontrolled Transaction Analysis for the Legacy IP Royalty Rate, dated November 2022. This report was prepared by Dr. Helena Vasquez, Managing Director, and her team at Whitmore Valuation Group LLC, at the direction of Calderwood & Harkness LLP, in connection with the IRS examination of PPC's Tax Years 2017–2020. The report applies the CUT method under Treas. Reg. § 1.482-4(c) to evaluate the arm's-length nature of the 4.5% royalty rate charged to PBI for the right to exploit pre-CSA intangible property (legacy IP) in non-Americas territories.
6.2 | Identification and Screening of 14 Comparable Uncontrolled Pharmaceutical License Agreements. The report describes the search methodology used to identify comparable uncontrolled transactions, including searches of the Calderon Data Systems, Harborline Services Inc., and RoyaltySource databases, together with public filings and industry publications. The initial search identified 78 potentially comparable license agreements, which were screened using comparability criteria based on the nature of the licensed intangible property (pharmaceutical compounds), the therapeutic area (oncology, immunology, and rare disease), the stage of commercialization (post-approval), the geographic scope of the license (international / non-U.S.), and the compensation structure (running royalty on net sales). After applying these screening criteria and conducting detailed comparability analyses, 14 agreements were retained as comparable.
6.3 | Comparability Analysis under Treas. Reg. § 1.482-4. The report presents a detailed comparability analysis for each of the 14 retained comparable agreements, evaluating the five comparability factors specified in Treas. Reg. § 1.482-4(c)(2): (i) the terms of the transfer, (ii) the functions performed, risks assumed, and resources employed by the parties, (iii) the contractual terms, (iv) the economic conditions, and (v) the property or services involved. The analysis includes adjustments for material differences between the comparable transactions and the controlled transaction, including differences in the stage of development of the licensed intangible property, the geographic scope of the license, and the licensee's role in commercialization.
6.4 | Interquartile Range: 3.1%–6.8%; Median: 4.4%. The 14 comparable license agreements yielded running royalty rates on net sales ranging from 2.0% to 9.5%. After application of the interquartile range methodology, the arm's-length range was established at 3.1% (25th percentile) to 6.8% (75th percentile), with a median of 4.4%. PPC's 4.5% royalty rate falls slightly above the median of the interquartile range, confirming that the rate is within the arm's-length range.
6.5 | Conclusion: PPC's 4.5% Royalty Rate Within Arm's-Length Range. The report concludes that the 4.5% royalty rate charged to PBI under the Legacy IP License Agreement is consistent with rates observed in comparable uncontrolled pharmaceutical license agreements and is within the arm's-length range established by the CUT analysis. No adjustment to PPC's reported royalty rate is warranted.
6.6 | Critique of IRS's Proposed 11.0% Rate and IRS-Selected CUT Data. The report identifies and critiques the methodological deficiencies in the IRS's alternative CUT analysis conducted by IRS Economist Dr. Alan Washburne. Specifically, the report demonstrates that: (i) several of the IRS-selected comparable agreements involve early-stage or pre-approval intangible property, which commands significantly higher royalty rates than fully commercialized, post-approval compounds; (ii) the IRS failed to make appropriate adjustments for differences in the geographic scope of the licenses; (iii) the IRS included agreements involving combination products and platform technologies, which are not comparable to the legacy compounds at issue; and (iv) the IRS's 11.0% rate falls outside the interquartile range of even the IRS's own selected comparables when appropriate comparability adjustments are applied.
6.7 | Supporting Data Tables and Comparable Agreement Summaries. The report includes detailed data tables for each of the 14 comparable license agreements, including the names of the parties (where publicly available), the therapeutic area, the stage of development at the time of licensing, the geographic scope, the royalty rate, and other key terms. The data tables also include the search methodology documentation, screening logs, and statistical calculations for the interquartile range determination.
Sub-Tab | Document Description
7.1 | Whitmore Valuation Group LLC — Comparable Profits Method / Transactional Net Margin Method Analysis Report, dated November 2022. This report was prepared by Dr. Helena Vasquez and her team to evaluate the arm's-length nature of PBI's operating margins during Tax Years 2017–2020, applying the CPM under Treas. Reg. § 1.482-5 (the U.S. equivalent of the TNMM under the OECD Transfer Pricing Guidelines). The analysis tests PBI as the "tested party" by comparing its operating profit margins to those of comparable independent companies performing similar functions, bearing similar risks, and employing similar assets.
7.2 | Search and Selection of 22 Comparable Distributors and IP-Holding Companies. The report describes the systematic search process used to identify comparable companies, including searches of the Fenmore Services Inc., Bureau van Dijk Orbis, and Westmark Services Inc. databases. The initial search population of 147 companies was screened based on criteria including industry classification (pharmaceutical / biopharmaceutical), functional profile (distribution, marketing, and limited-risk exploitation of licensed intangible property), geographic focus (international / ex-U.S. markets), size and scale, data availability for the relevant examination period, and the absence of controlled transactions that would distort the comparables' financial results. Twenty-two companies were retained as comparable after applying these screening criteria and conducting detailed functional comparability reviews.
7.3 | PBI's Operating Margins Tested Against Interquartile Range for All Four Years (2017–2020). The report presents PBI's operating margins for each of the four examination years, computed on a consistent basis with the comparable companies, and tests these margins against the interquartile range derived from the comparable set. The results confirm that PBI's operating margins fall within the interquartile range in each of the four examination years, as summarized below:
Tax Year | PBI Operating Margin | IQR (25th–75th) | Within IQR?
2017 | 46.2% | 38.7%–52.4% | Yes
2018 | 47.8% | 39.1%–53.6% | Yes
2019 | 49.1% | 40.3%–54.2% | Yes
2020 | 49.6% | 41.0%–55.1% | Yes
Sub-Tab | Document Description
7.4 | Conclusion: PBI's Margins Within IQR in Each Year. The report concludes that PBI's operating margins are consistent with arm's-length results in each of the four examination years, and that no adjustment to PBI's profitability is warranted under the CPM/TNMM. The analysis confirms that the intercompany pricing between PPC and PBI, including the CSA cost-sharing payments and the Legacy IP royalty, produces profit allocations that are consistent with the returns earned by comparable independent companies performing comparable functions, bearing comparable risks, and employing comparable assets.
7.5 | Compliance with Best Method Rule under Treas. Reg. § 1.482-1(d). The report addresses the application of the best method rule and explains why the CUT method is the most reliable method for testing the Legacy IP royalty rate, while the CPM/TNMM serves as a corroborative method. The report discusses the relative reliability of the available data, the degree of comparability between the controlled and uncontrolled transactions, and the number and magnitude of the adjustments required, all of which support the selection of the CUT as the primary method and the CPM/TNMM as a confirmatory analysis.
Sub-Tab | Document Description
8.1 | Whitmore Valuation Group LLC — PCT Valuation Report (Income Method / DCF Approach), dated December 2022. This report was prepared by Dr. Helena Vasquez and Dr. Rohan Chakrabarti of Whitmore Valuation Group LLC to determine the arm's-length value of the platform contribution transaction payment required under PPC's qualified cost-sharing arrangement. The report applies the income method under Treas. Reg. § 1.482-7(g)(4), using a discounted cash flow approach to value PBI's share of the reasonably anticipated benefits from the pre-existing intangible property contributed by PPC to the CSA as of the CSA effective date of July 1, 2012.
8.2 | Revenue Projection Methodology — Americas vs. Non-Americas Splits for Veritaxol, Imvara, and Cerulon. The report describes the methodology used to project PBI's share of future revenues from the exploitation of cost-shared intangible property in non-Americas territories for each of PPC's three principal products: Veritaxol (oncology), Imvara (immunology), and Cerulon (rare disease). The projections are based on product-level market models incorporating therapeutic area market size, expected market share, pricing trends, patent life, regulatory approval timelines, and competitive dynamics. The Americas/non-Americas revenue splits are derived from historical data and market-specific growth assumptions, consistent with the methodology prescribed by Treas. Reg. § 1.482-7(g)(4)(vi).
8.3 | WACC Determination: PPC/Calderwood & Harkness Position at 9.8% vs. IRS Position at 7.2%. The report presents the derivation of the weighted-average cost of capital ("WACC") used to discount PBI's projected future cash flows from the exploitation of cost-shared intangible property. The taxpayer's WACC of 9.8% reflects the risk profile of pharmaceutical intangible property, including clinical development risk, regulatory approval risk, commercial risk, and reimbursement risk in non-Americas markets. The IRS's proposed WACC of 7.2% is identified as insufficiently accounting for the specific risks associated with pharmaceutical intangible property and the non-Americas market territories. A detailed analysis of the components of the WACC determination, including the risk-free rate, equity risk premium, beta, size premium, and debt/equity structure, is provided.
8.4 | Arm's-Length Range for PCT: $278,000,000–$361,000,000; $312,000,000 Actual Payment Within Range. The DCF analysis produces an arm's-length range for the PCT payment of $278,000,000 to $361,000,000, based on reasonable variations in key valuation assumptions (including the WACC, revenue growth rates, and terminal value methodology). The $312,000,000 payment actually made by PBI falls within this range, confirming that the PCT payment is consistent with the arm's-length standard.
8.5 | IRS's Income-Method Valuation at $852,000,000 — Identification of Methodological Errors. The report critiques the IRS's alternative PCT valuation of $852,000,000, which was prepared by IRS Economist Dr. Alan Washburne. The report identifies the following methodological errors in the IRS's valuation: (i) application of an inappropriately low WACC of 7.2%, which fails to account for the specific risks of pharmaceutical IP in non-Americas markets (see Tab 9 for detailed WACC analysis); (ii) overstated non-Americas revenue growth projections that are inconsistent with contemporaneous market data and industry forecasts; (iii) an excessively long explicit projection period that extends beyond the useful life of the contributed intangible property; (iv) failure to account for generic competition and patent expiry for key legacy compounds; and (v) use of an inappropriate terminal value methodology that inflates the present value of future cash flows.
Sub-Tab | Document Description
9.1 | Dr. Helena Vasquez — WACC Analysis Memorandum, dated December 2022. This technical memorandum was prepared by Dr. Helena Vasquez, Managing Director of Whitmore Valuation Group LLC, to provide a detailed analysis of the appropriate WACC for use in valuing PBI's reasonably anticipated benefits from the cost-shared intangible property. The memorandum presents the full build-up of the taxpayer's 9.8% WACC and provides a rigorous critique of the IRS's 7.2% WACC.
9.2 | Risk Premium Analysis, Beta Comparables, and Pharmaceutical-Industry Cost of Capital Data. The memorandum presents detailed supporting data for the WACC determination, including: (i) a survey of equity risk premiums and size premiums for mid-cap pharmaceutical companies, using data from Westmark Consulting Group (now Sundial Advisors) and Bramwell Technologies; (ii) a beta analysis using a set of 18 publicly traded pharmaceutical and biopharmaceutical companies comparable to PPC's risk profile, with levered betas ranging from 0.85 to 1.42 (median 1.12); (iii) a survey of published pharmaceutical-industry cost of capital studies, including studies by Damodaran, Westvale Advisors, and the Tufts Center for the Study of Drug Development; and (iv) an analysis of the incremental risk associated with non-Americas market territories, including emerging markets with higher regulatory, pricing, reimbursement, and currency risks.
9.3 | Critique of IRS's Application of 7.2% WACC — Insufficient Risk Adjustment, Inappropriate Peer Selection. The memorandum demonstrates that the IRS's 7.2% WACC is materially too low because: (i) the IRS used a peer group of large-cap diversified pharmaceutical companies with lower risk profiles than PPC's specialty pharmaceutical portfolio; (ii) the IRS's peer group included companies with significant consumer health and generic drug divisions, which have lower betas and cost of capital than innovative specialty pharma; (iii) the IRS failed to apply a size premium appropriate for PPC's market capitalization; (iv) the IRS failed to make adjustments for the incremental risk of non-Americas market exploitation, including regulatory risk in emerging markets and currency risk; and (v) the IRS's risk-free rate assumption was based on a spot rate rather than a normalized rate consistent with the long-term projection period.
9.4 | Support for 9.8% WACC as More Appropriate for Pharmaceutical IP with Clinical and Commercial Risk. The memorandum concludes that a WACC of 9.8% is the most appropriate discount rate for valuing PBI's reasonably anticipated benefits from the cost-shared intangible property, based on the specific risk characteristics of PPC's oncology, immunology, and rare disease product portfolio; the incremental risk associated with non-Americas market exploitation; and the empirical evidence from comparable company betas, published industry studies, and pharmaceutical-specific risk premium data. The 260-basis-point difference between the taxpayer's 9.8% WACC and the IRS's 7.2% WACC has a material impact on the PCT valuation, accounting for approximately $340,000,000 of the $540,000,000 difference between the taxpayer's $312,000,000 PCT value and the IRS's $852,000,000 PCT value.
Sub-Tab | Document Description
10.1 | Benchmarking Study Workbook — Search Criteria, Screening Methodology, and Financial Data. This workbook contains the complete documentation of the benchmarking searches conducted by Whitmore Valuation Group LLC to identify comparable transactions (for the CUT analysis) and comparable companies (for the CPM/TNMM analysis). The workbook includes the search parameters, database queries, initial results, screening criteria, rejection logs (with reasons for exclusion), and the final sets of retained comparables. Financial data for the retained comparables is presented on a consistent basis, with adjustments for accounting differences where applicable.
10.2 | 14 CUT Comparable License Agreement Profiles. Individual profiles for each of the 14 comparable pharmaceutical license agreements retained for the CUT analysis, including: the names of the parties (where publicly disclosed), the date of the agreement, the therapeutic area and product description, the geographic scope, the stage of development, the royalty rate, other consideration (milestones, upfront payments), the key terms and obligations of the parties, and the comparability assessment relative to the PPC–PBI Legacy IP License Agreement.
10.3 | 22 CPM/TNMM Comparable Company Profiles. Individual profiles for each of the 22 comparable companies retained for the CPM/TNMM analysis, including: the company name, jurisdiction, functional profile, industry classification, revenue, operating income, operating margin, total assets, number of employees, and the period of financial data used. The profiles include a functional comparability assessment for each company relative to PBI.
10.4 | IQR Calculations and Statistical Summaries. This section contains the statistical calculations supporting the interquartile range determinations for both the CUT analysis (royalty rates) and the CPM/TNMM analysis (operating margins), including the full distribution of data points, the calculation of the 25th percentile, median, and 75th percentile, and sensitivity analyses illustrating the impact of including or excluding specific comparables on the interquartile range.
Sub-Tab | Document Description
11.1 | Cost-Sharing Ratio Analysis Workbook — Reasonably Anticipated Benefit Projections. This workbook contains the detailed calculations of PBI's share of reasonably anticipated benefits for each of the four examination years, based on PBI's projected share of non-Americas revenue relative to global revenue from cost-shared intangible property. The methodology is consistent with the requirements of Treas. Reg. § 1.482-7(e)(1), which requires that each CSA participant's share of intangible development costs be proportional to its share of reasonably anticipated benefits from exploitation of the cost-shared intangibles.
11.2 | PBI Shares by Year with Supporting Revenue Projections. The workbook presents PBI's cost-sharing percentages and the corresponding cost-sharing payments for each examination year:
Tax Year | PBI Share | Total Qualified R&D Costs | PBI Payment
2017 | 38.2% | $487,300,000 | $186,150,000
2018 | 39.6% | $523,800,000 | $207,420,000
2019 | 41.1% | $561,200,000 | $230,650,000
2020 | 42.7% | $598,400,000 | $255,520,000
Sub-Tab | Document Description
11.3 | Sensitivity Analyses Comparing PPC's Ratios to IRS Proposed Ratios. The workbook includes sensitivity analyses illustrating the impact of alternative revenue projection assumptions on PBI's cost-sharing percentages. These analyses demonstrate that the IRS's proposed ratios (2017: 48.2%; 2018: 50.6%; 2019: 52.3%; 2020: 53.7%) can only be achieved by adopting revenue projection assumptions that are materially inconsistent with contemporaneous market data, including overstated non-Americas revenue growth rates, understated Americas revenue, and failure to account for the impact of generic competition in non-Americas territories.
11.4 | Total Qualified R&D Costs by Year. Summary of the total qualified intangible development costs included in the CSA cost pool for each examination year ($487,300,000 in 2017; $523,800,000 in 2018; $561,200,000 in 2019; and $598,400,000 in 2020). The workbook includes a breakdown of the cost pool by functional category (basic research, clinical development, regulatory affairs, medical affairs, and manufacturing process development) and identifies all costs included and excluded from the cost pool in accordance with Treas. Reg. § 1.482-7(d)(1).
Sub-Tab | Document Description
12.1 | Americas vs. Non-Americas Revenue Projections for 2017–2020. This section presents the actual revenue data (used retrospectively to verify the reasonably anticipated benefit projections) for PPC's cost-shared products, broken down by Americas and non-Americas territories, for each of the four examination years.
12.2 | Product-Level Data. Revenue data for each of PPC's three principal cost-shared products, with global and non-Americas net sales for 2020 as follows:
Product | Therapeutic Area | 2020 Global Net Sales | 2020 Non-Americas Net Sales | Non-Americas %
Veritaxol | Oncology | $3,120,000,000 | $1,340,000,000 | ~43%
Imvara | Immunology | $1,870,000,000 | $790,000,000 | ~42%
Cerulon | Rare Disease | $620,000,000 | $280,000,000 | ~45%
Sub-Tab | Document Description
12.3 | Legacy Compound Net Sales, Non-Americas. Net sales of legacy compounds (pre-CSA intangible property) in non-Americas territories, to which the 4.5% royalty rate applies under the Legacy IP License Agreement:
Tax Year | Non-Americas Legacy Compound Net Sales
2017 | $814,600,000
2018 | $762,300,000
2019 | $691,800,000
2020 | $624,100,000
Sub-Tab | Document Description
12.4 | Reasonably Anticipated Benefit Calculation Methodology under Treas. Reg. § 1.482-7. This section describes the methodology used to calculate PBI's reasonably anticipated benefits from the exploitation of cost-shared intangible property, consistent with the requirements of Treas. Reg. § 1.482-7(e)(1). The methodology uses forward-looking revenue projections for each cost-shared product, allocated between Americas and non-Americas territories based on market models that incorporate product-specific factors (therapeutic area, competitive positioning, patent life, regulatory status) and territory-specific factors (market size, pricing, reimbursement, population demographics, healthcare infrastructure).
Sub-Tab | Document Description
13.1 | Royalty Payment Comparison: PPC's 4.5% Rate vs. IRS's 11.0% Rate Across All Four Years. This financial model calculates the royalty payments under both the taxpayer's rate and the IRS's proposed rate, using the actual non-Americas legacy compound net sales data for each examination year, and quantifies the resulting adjustment delta.
13.2 | Year-by-Year Calculations. The financial model presents the following year-by-year calculations:
Tax Year | Legacy Net Sales (Non-Americas) | Royalty at 4.5% | Royalty at 11.0% | Adjustment Delta
2017 | $814,600,000 | $36,660,000 | $89,610,000 | $52,950,000
2018 | $762,300,000 | $34,300,000 | $83,850,000 | $49,550,000
2019 | $691,800,000 | $31,130,000 | $76,100,000 | $44,970,000
2020 | $624,100,000 | $28,080,000 | $68,650,000 | $40,570,000
Total | $2,892,800,000 | $130,170,000 | $318,210,000 | $188,040,000
Sub-Tab | Document Description
13.3 | Total Royalty Adjustment Delta: $188,040,000. The total difference between the royalty payments at the taxpayer's 4.5% rate and the IRS's proposed 11.0% rate, across all four examination years, is $188,040,000. This amount represents the royalty adjustment component of the IRS's total proposed adjustment of $380,400,000.
Sub-Tab | Document Description
14.1 | Whitmore Valuation Group LLC — Rebuttal Memorandum, prepared by Dr. Helena Vasquez and Dr. Rohan Chakrabarti, dated January 2024. This memorandum was prepared at the direction of Calderwood & Harkness LLP in response to the economic analysis prepared by IRS Economist Dr. Alan Washburne, which was provided to the taxpayer as part of the NOPA issued on October 12, 2023. The rebuttal memorandum addresses each of the principal methodological issues identified in Dr. Washburne's analysis.
14.2 | Critique of Dr. Washburne's CUT Selection Criteria — Insufficient Comparability Adjustments. The rebuttal demonstrates that Dr. Washburne's CUT analysis is unreliable because: (i) his initial search identified only 9 comparable license agreements, compared to the taxpayer's 14, reflecting an overly narrow search methodology; (ii) several of Dr. Washburne's selected comparables involve early-stage, pre-approval pharmaceutical compounds with materially different risk profiles and expected royalty rates; (iii) Dr. Washburne failed to make comparability adjustments required under Treas. Reg. § 1.482-4(c)(2) for differences in the stage of development, the geographic scope, and the exclusivity of the licenses; and (iv) Dr. Washburne's interquartile range, when properly adjusted for comparability, produces results consistent with the taxpayer's CUT analysis rather than supporting an 11.0% royalty rate.
14.3 | Critique of discount Rate Assumptions (7.2% WACC Insufficiently Accounts for Pharmaceutical R&D Risk). The rebuttal incorporates the analysis from Tab 9, demonstrating that Dr. Washburne's 7.2% WACC is materially too low for pharmaceutical intangible property with clinical development, regulatory, and commercial risk in non-Americas markets. The rebuttal shows that Dr. Washburne's peer group is not comparable to PPC's risk profile, and that his failure to apply appropriate risk adjustments results in a PCT valuation that is overstated by approximately $540,000,000.
14.4 | Critique of Projected Revenue Growth Rates — Overstated Non-Americas Growth, Inconsistent with Market Data. The rebuttal demonstrates that Dr. Washburne's revenue growth projections for non-Americas territories are materially overstated relative to contemporaneous market data, industry consensus forecasts, and PPC's own internal projections. Specifically, Dr. Washburne assumes compound annual growth rates for non-Americas revenue that are 3–5 percentage points higher than the consensus forecasts published by Tidewater Holdings, Harborline Services Inc., and other industry sources at the time of the CSA effective date. The rebuttal further demonstrates that Dr. Washburne's projections do not account for the impact of generic competition, regulatory pricing pressures, and market access barriers in key non-Americas territories.
14.5 | Summary of Methodological Deficiencies in IRS Economist's Analysis. The rebuttal concludes with a summary of all identified methodological deficiencies in Dr. Washburne's analysis, organized by issue (CUT analysis, PCT valuation, and cost-sharing ratio calculation). The summary identifies 14 specific methodological errors and their individual and cumulative impact on the IRS's proposed adjustments.
Sub-Tab | Document Description
15.1 | Proposed Adjustment Summary Workbook — Breakdown by Issue and Year. This workbook provides a consolidated view of the IRS's proposed adjustments for each of the three adjustment issues (CSA cost-sharing, legacy IP royalty rate, and correlative offset), organized by tax year, with rollups to total proposed adjustments by issue and by year.
15.2 | CSA Adjustments by Year:
Tax Year | CSA Adjustment
2017 | $48,730,000
2018 | $57,610,000
2019 | $62,850,000
2020 | $65,820,000
Total | $235,010,000
Sub-Tab | Document Description
15.3 | Royalty Adjustments by Year:
Tax Year | Royalty Adjustment
2017 | $52,950,000
2018 | $49,550,000
2019 | $44,970,000
2020 | $40,570,000
Total | $188,040,000
Sub-Tab | Document Description
15.4 | Correlative Offset: ($42,650,000). The IRS has allowed a correlative offset of $42,650,000 to avoid double-counting between the CSA cost-sharing adjustments and the royalty rate adjustments, reflecting the interaction between the two adjustment categories.
15.5 | Net Proposed Adjustment: $380,400,000. The total net proposed adjustment across all four examination years, after application of the correlative offset, is $380,400,000.
15.6 | Tax and Penalty Impact Calculations. The workbook calculates the federal income tax and penalty exposure arising from the IRS's proposed adjustments:
Component | Calculation | Amount
Net Proposed Adjustment | $380,400,000
Federal Income Tax (21%) | $380,400,000 × 21% | $79,884,000
IRC § 6662(e) Penalty (20%) | $79,884,000 × 20% | $15,977,000
Total Tax and Penalty Exposure | $95,861,000
Sub-Tab | Document Description
16.1 | Comprehensive Functional Analysis, prepared jointly by Calderwood & Harkness LLP and Whitmore Valuation Group LLC, initially dated October 2022 and revised March 15, 2023. This functional analysis describes the functions performed, assets employed, and risks assumed by PBI during Tax Years 2017 through 2020 in connection with the exploitation of cost-shared and legacy intangible property in non-Americas territories. The analysis was prepared to support PPC's transfer pricing positions and was provided to the IRS examination team in response to Information Document Request No. 12, issued August 10, 2022.
16.2 | PBI's Functions. The functional analysis identifies and describes the following principal function